As a novel targeted immunotherapy, chimeric antigen receptor T (CAR T) cells have exerted excellent efficacy in hematologic malignancies 3, which can specifically recognize tumor cells expressing target antigens without MHC molecule processing and presentation, rapidly initiating killing function and achieving accurate tumor clearance 4, 5. Here, HLA-C is linked to neoplasm.